Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy
NCT ID: NCT05494528
Last Updated: 2022-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
90 participants
INTERVENTIONAL
2021-05-04
2024-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects will be treated with 450 µg of P1101 every two weeks or with 0.5 mg of Entecavir monotherapy once per day. Primary endpoint will be evaluated at week 48. Subjects will receive treatment with a total duration of 72 weeks. The follow-up (treatment-free) period is 24 weeks following completion of treatment. Switch from the other nucleos(t)ide analogue therapy to entecavir will occur at week 0 (Randomization), while the dose of Entecavir will be 0.5 mg.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ropeginterferon alfa-2b monotherapy
Subjects will be treated with 450 µg of Ropeginterferon alfa-2b every two weeks
Ropeginterferon alfa-2b
Ropeginterferon alfa-2b 450 µg subcutaneous injection every two weeks
Entecavir monotherapy
Subjects will be treated with 0.5 mg of Entecavir monotherapy once per day
Entecavir
Entecavir 0.5 mg once per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ropeginterferon alfa-2b
Ropeginterferon alfa-2b 450 µg subcutaneous injection every two weeks
Entecavir
Entecavir 0.5 mg once per day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of chronic hepatitis B (CHB) virus infection: with positive HBsAg ≧ 6 months prior to the study entry;
* Quantitative HBsAg level \< 1,500 IU/ml at screening;
* Confirmed HBeAg (-) at screening;
* Stable disease: ALT \< 3 x upper limit of normal (ULN), total bilirubin \< 1.5 × ULN (except in Gilbert syndrome) and direct bilirubin \< ULN at screening, serum HBV DNA \< 50 IU/mL for ≧ 1 year prior to study entry;
* Stable treatment with nucleos(t)ide regimen (adefovir, entecavir, tenofovir or one of the following combinations: entecavir/adefovir or entecavir/tenofovir) for at least 2 years prior to study entry;
* Interferon treatment naïve;
* Normal fundoscopic examination by ophthalmologist at screening; defined as no significant or major fundoscopic findings including but not limited to retinal exudates, hemorrhage, detachment, neovascularization, papilloedema, optic atrophy, microaneurysms and macular changes;
* Be able to attend all scheduled visits and to comply with all study procedures;
* Be able to provide written informed consent.
Exclusion Criteria
* Documented history of drug resistance to any nucleoside/ nucleotide analogue;
* History of treatment with lamivudine or telbivudine prior to the study entry;
* Clinically significant abnormalities, other than HBV infection, based upon the results of a medical history, physical examination, vital signs, and a 12-lead electrocardiogram (ECG) at screening as determined by the investigator;
* Other form of significant chronic liver disease apart from chronic hepatitis B infection; Severe steatohepatitis by ultrasound or other examinations at the discretion of investigators;
* Liver cirrhosis;
* Known positive for anti-HIV;
* Positive for anti-hepatitis C virus(HCV), Subject could be enrolled if no HCV RNA detected within 1 year；
* Co-infection with hepatitis D;
* One of clinically significant abnormal laboratory test result at screening: white blood cell (WBC) \< 3,000/mm\^3, absolute neutrophil count (ANC) \< 1500/mm\^3, Hgb \< 10g/dL, platelet \< 90,000/mm\^3, estimated Glomerular filtration rate \< 60 mL/min;
* History of significant alcohol or illicit drug abuse within six months prior to the screening visit (alcohol consumption of more than fourteen units of alcohol per week \[1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol\]) or refusal to abstain from illicit drugs and minimize alcohol consumption throughout the study;
* History of severe allergic or hypersensitivity reactions (e.g bronchospasm, angioedema), asthma, or anaphylaxis
* Therapy with any systemic anti-viral treatment (except for treatment for HBV), anti-neoplastic, immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) and immunosuppressants within 1 month (3 months for those with long elimination half-lives) prior to the first dose of study drug;
* Use of an investigational drug within the last 4 weeks;
* Any history or presence of poorly controlled or clinically significant medical conditions that are not suitable to receive interferon-based treatment, at the discretion of the investigator: major psychiatric (including but not limited to those with severe depression, severe bipolar disorder, schizophrenia, suicidal ideation or history of suicidal attempt),neurological, cardiovascular (e.g. uncontrolled hypertension), pulmonary (including but not limited to chronic obstructive lung disease), hematological, immunologic, endocrine, metabolic (e.g. diabetes mellitus with HbA1C \> 8.0%), autoimmune disease, thyroid or other uncontrolled systemic disease, coagulation disorders or blood dyscrasias;
* A depot injection or an implant of any drug within 3 months prior to administration of study medication, other than contraception or hyaluronic acid injections in joints for osteoarthritis;
* History of solid organ transplantation;
* History of malignancy diagnosed or treated within 5 years prior to screening (except for recent localized treatment of squamous or noninvasive basal cell skin cancers; cervical carcinoma in situ), cancer survivors not on maintenance therapy within the past 5 years;
* History of opportunistic infection (e.g., invasive candidiasis or pneumocystis pneumonia)
* Serious localized infection (e.g., cellulitis, abscess) or systemic and life-threatening infection (e.g., septicemia) within the 3 months prior to screening;
* Pregnant subjects. Female subjects or the spouse of male subjects, with child-bearing potential who are unwilling or unable to practice adequate contraception, defined as vasectomy in men, tubal ligation in women, or use of condoms and spermicides, or birth control pills, or intrauterine devices from 4 weeks prior to Day 1 until 90 days after the last dose of study drug.
20 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
PharmaEssentia
INDUSTRY
National Taiwan University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chun-Jen Liu
Role: PRINCIPAL_INVESTIGATOR
National Taiwan University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, , Taiwan
China Medical University Hospital
Taichung, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Taipei Medical University Hospital
Taipei, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Chia-Yen Dai
Role: primary
Cheng-Yuan Peng
Role: primary
Chun-Jen Liu
Role: primary
Yi-Wen Huang
Role: primary
Yi-Hsiang Huang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A18-I02
Identifier Type: OTHER
Identifier Source: secondary_id
202003098MIPD
Identifier Type: -
Identifier Source: org_study_id